Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT05993442

Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.

Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU. — Recruiting • Non-phase study • Infectious Disease • NCT05993442.

📅 25 Mar 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT05993442
Sponsor
PENTA Foundation
Start
2024-05-28
ClinicaliQ Trial Snapshot
  • Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU. — Recruiting • Non-phase study • Infectious Disease • NCT05993442.
  • NeoDeco is a pragmatic, multicenter, parallel-group, cluster-randomised hybrid effectiveness-implementation trial designed to evaluate the impact of implementing optimised Kangaroo Care (KC) at the unit level compared to standard care in high-technology neonatal units. The trial includes a baseline period, a wash-in phase,….
  • Sponsor: PENTA Foundation.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

NeoDeco is a pragmatic, multicenter, parallel-group, cluster-randomised hybrid effectiveness-implementation trial designed to evaluate the impact of implementing optimised Kangaroo Care (KC) at the unit level compared to standard care in high-technology neonatal units. The trial includes a baseline period, a wash-in phase, and a staggered randomisation approach. The primary focus of the NeoDeco study is on high-risk preterm infants born at less than 32 weeks' gestational age, a population particularly vulnerable to hospital-acquired infections and sepsis during their initial hospital stay. By investigating hospital-acquired infections specifically, the study targets the…

Eligibility Snapshot
  • Site level 1a. Neonatal unit that provide routinely cares for extremely premature infants (

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Pregnancy vaccine reduces baby hospital admissions for RSV by 80%
Infectious Disease · BBC Health · 17 Apr 2026
Maternal RSV vaccination reduces infant hospitalisation risk by 80%, offering significant protection against severe lower respiratory tract infection in the first months…
View brief →
Guideline
HIV Testing: Increasing Uptake Among People Who May Have Undiagnosed HIV (NICE PH33)
Infectious Disease · 27 Mar 2026
Offer opt-out HIV testing in emergency departments, sexual health clinics, and antenatal services to maximise identification of undiagnosed HIV cases without requiring…
View guideline →
Clinical Brief
Why is MenB vaccine not given to teenagers in UK and should they be offered it?
Infectious Disease · BBC Health · 24 Mar 2026
Students and older teens are not routinely vaccinated against the meningitis strain behind the Kent outbreak. This update is most useful for…
View brief →
Guideline
Sepsis: Recognition, Diagnosis and Early Management (NICE NG51)
Infectious Disease · 27 Mar 2026
Use qSOFA tool (altered mental state, systolic BP ≤100 mmHg, respiratory rate ≥22) or NEWS2 score to identify suspected sepsis in adults…
View guideline →
Clinical Brief
RSV maternal vaccine cuts baby hospital admissions by up to 85%
Infectious Disease · UKHSA · 17 Apr 2026
RSV maternal vaccination during pregnancy reduces hospital admissions in infants by up to 85%, with largest protective effect in premature babies, according…
View brief →
Clinical Brief
Increase in drug-resistant Shigella cases among gay and bisexual men
Infectious Disease · UKHSA · 26 Mar 2026
New UKHSA data shows that sexually transmitted Shigella cases in England continue to occur at high levels, with over 2,500 diagnoses in…
View brief →